Literature DB >> 1489898

Evidence for activation of coagulation in Crohn's disease.

M Hudson1, R A Hutton, A J Wakefield, A M Sawyerr, R E Pounder.   

Abstract

Haemostatic changes in 16 patients with Crohn's disease were studied from active disease into clinical remission and beyond. Elevated concentrations of fibrinopeptide A (FpA) and prothrombin fragments F1 + 2 (F1 + 2) were found at times of both active (FpA median 3.2, range [0.3-40] ng/ml and F1 + 2 median 2.3, range [0.3-18] nm/l) and inactive disease (FpA median 2, range [0.4-40] ng/ml and F1 + 2 median 1.3, range [0.2-20) nm/l]. We also measured the physiological inhibitors of coagulation and fibrinolysis; there was no significant difference in the levels of antithrombin III, protein C or the Exner ratio between active and inactive disease. Free protein S levels were significantly lower in active disease (median 34, range 9-54 U/dl) than in remission (median 40, range 12-65 U/dl). Plasminogen activator inhibitor type 1 (PAI-1) was significantly raised in remission (median 11, range 3-32 ng/ml) when compared to active disease (median 7, range 3-42 ng/ml). The D-dimer correlated significantly with fibrinopeptide A (P < 0.001), suggesting reactive fibrinolysis in some patients. Most (35/52, 67%) samples showed evidence of persistent haemostatic activation (elevated FpA and/or F1 + 2) during phases of apparent clinical remission in Crohn's disease, a factor that is not reflected by clinical activity scores. This study supports the hypothesis that coagulation is activated in the mesenteric vasculature of patients with Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1489898     DOI: 10.1097/00001721-199212000-00011

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  24 in total

1.  Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications.

Authors:  N Mahmud; A Molloy; J McPartlin; R Corbally; A S Whitehead; J M Scott; D G Weir
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo.

Authors:  Frank M Szaba; Stephen T Smiley
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

4.  Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis.

Authors:  A Stadnicki; M Gonciarz; T J Niewiarowski; J Hartleb; M Rudnicki; N B Merrell; R A Dela Cadena; R W Colman
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

5.  Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives.

Authors:  C Folwaczny; N Noehl; S P Endres; W Heldwein; K Loeschke; H Fricke
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

6.  Increased expression of L-plastin in nasal polyp of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.

Authors:  Tetsuji Takabayashi; Yukie Tanaka; Dai Susuki; Kanako Yoshida; Kaori Tomita; Masafumi Sakashita; Yoshimasa Imoto; Yukinori Kato; Norihiko Narita; Tsugihisa Nakayama; Shinichi Haruna; Robert P Schleimer; Shigeharu Fujieda
Journal:  Allergy       Date:  2018-12-17       Impact factor: 13.146

7.  Increased expression of factor XIII-A in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Tetsuji Takabayashi; Atsushi Kato; Anju T Peters; Kathryn E Hulse; Lydia A Suh; Roderick Carter; James Norton; Leslie C Grammer; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2013-03-28       Impact factor: 10.793

Review 8.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

9.  Immunohistochemical study of tissue factor expression in normal intestine and idiopathic inflammatory bowel disease.

Authors:  L More; R Sim; M Hudson; A P Dhillon; R Pounder; A J Wakefield
Journal:  J Clin Pathol       Date:  1993-08       Impact factor: 3.411

10.  Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease.

Authors:  J C Souto; E Martínez; M Roca; J Mateo; J Pujol; D González; J Fontcuberta
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.